By Fineline Cube 
French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net sales of EUR 9.9 billion (USD 11.25 billion), marking a 9.7% year-on-year (YOY) expansion in constant currency terms.
Key Drug Performance
Dupixent (dupilumab), Sanofi’s flagship allergy and asthma therapy, continued its growth trajectory with a 20.3% YOY increase to EUR 3.48 billion (USD 3.96 billion). Lantus (insulin glargine) also showed strong growth, rising by 24.4% to EUR 450 million (USD 512 million).
New Launches and Vaccines
The eight drugs classified as new launches generated EUR 847 million in sales, up 43.8% YOY. Hemophilia therapy Altuviiio (recombinant factor VIII) led the charge with 100% growth to EUR 251 million (USD 285 million). The vaccines segment saw a 11.4% YOY increase to EUR 1.33 billion (USD 1.51 billion), driven by a 54.9% surge in respiratory syncytial virus (RSV) vaccine Beyfortus sales to EUR 284 million (USD 323 million).
Regional Performance
US sales were the primary driver of growth, increasing by 15.4% YOY to EUR 4.66 billion (USD 5.3 billion). European sales remained relatively flat at 0.5% growth to EUR 2.04 billion (USD 2.3 billion). Rest of World (ROW) sales grew 8.4% to EUR 3.2 billion (USD 3.6 billion), though China sales within ROW declined by 1.7% to EUR 701 million (USD 797 million).
Management Comments and Guidance
During the earnings call, CFO Francois Rodger addressed questions about potential US tariffs, stating that while there are no specifics to share at this stage, the company has prepared for all scenarios. Sanofi reaffirmed its 2025 sales guidance, expecting mid-to-high single-digit percentage growth.-Fineline Info & Tech